Press Release

DAY HI:
DAY LOW:
VOLUME:

Copyright West LLC. Minimum 15 minutes delayed.

Spectrum Pharmaceuticals Highlights 18 Abstracts at the 57th Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida, December 5-8, 2015

December 4, 2015 at 7:00 AM EST

HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of clinical and scientific data related to its products at the 57th Annual Meeting of the American Society of Hematology (ASH), being held in Orlando, Florida, from December 5-8, 2015.

For more information about the ASH annual meeting and for a complete list of abstracts, please refer to the conference website at https://ash.confex.com/ash/2015/webprogram/start.html.

The following are key PTCL-related abstracts being presented at the ASH meeting:

                 
Abstract #   Type   Title  

First Author

 

Date/Time
Location

 

1562 Poster The Combination of Belinostat with Zidovudine for Treatment of HTLV-I Related Adult T-Cell Leukemia-Lymphoma Toomey

Saturday, Dec 5,

5:30 PM-7:30 PM

 

Hall A, Level 2

1282 Poster Targeting Epigenetic Operations with HDAC Inhibitor and Hypomethylating Drugs in Combination Exhibit Synergy in Preclinical and Clinical Experiences in Drug Resistant T-Cell Lymphoma (TCL): A Translational Focus on Doublet Development O'Connor

Saturday, Dec 5,

5:30 PM-7:30 PM

 

 

 

Hall A, Level 2

253 Oral Safe and Effective Treatment of Patients with Peripheral T-Cell Lymphoma (PTCL) with the Novel HDAC Inhibitor, Belinostat, in Combination with CHOP: Results of the Bel-CHOP Phase 1 Trial Johnston Sunday, Dec 6,

12:00 PM

 

W311, Level 3

315 Oral Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Anderson

Sunday, Dec 6,

5:00 PM

 

W304EFGH, Level 3

2677 Poster Results from a Phase 1/2, Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Duvic Sunday, Dec 6, 6:00 PM-8:00 PM

 

Hall A, Level 2

2753 Poster The Proteasome Inhibitor, Ixazomib, Combined with Novel Drug Combinations in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL): Identification of Key Genes and Signaling Pathways Via a Novel Systems Biology Approach Passero Sunday, Dec 6, 6:00 PM-8:00 PM

 

 

Hall A, Level 2

3966 Poster An Open-Label, Phase 1 Study Evaluating the Safety and Pharmacokinetics of Pralatrexate in Relapsed/Refractory Advanced Solid Tumors or Advanced Lymphoma/Myeloma Patients with Mild, Moderate, and Severe Renal Impairment Kelly Monday, Dec 7, 6:00 PM-8:00 PM

 

 

Hall A, Level 2

3984 Poster The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL Chihara Monday, Dec 7,

6:00 PM-8:00 PM

 

Hall A, Level 2

N/A   Publication Only   The Synergy Between Belinostat and Pralatrexate is Sequence Dependent in Lyphoma Cells in vitro   Peters   Publication Only
 

The following are key Marqibo® (vinCRIStine sulfate LIPOSOME injection) related abstracts being presented at the ASH meeting:

                 
Abstract #   Type   Title   First Author   Location
1291 Poster Marqibo®, Vincristine Sulfate Liposome Injection, for the Treatment of Advanced, Relapsed or Refractory Philadelphia Chromosome-Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) in an Adolescent Young Adult (AYA) Population Schiller Saturday, Dec 5,

5:30 PM-7:30 PM

 

 

 

Hall A, Level 2

2491 Poster Plasma Vincristine Levels Are 100-Fold Higher with Marqibo®(Vincristine Sulfate LIPOSOME Injection) in Place of Standard Vincristine in Combination Chemotherapy of Patients ≥ 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Wang Sunday, Dec 6,

6:00 PM-8:00 PM

 

 

 

Hall A, Level 2

3965 Poster The Clinical Outcome of Newly Diagnosed Patients &#62 60 Years of Age with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Standard or Liposomal Chemotherapies Ahmed Monday, Dec 7,

6:00 PM-8:00 PM

 

 

Hall A, Level 2

3720   Poster   Liposomal Vincristine (Marqibo) Combined with Hyper-Cmad As Frontline Therapy for Patients with Acute Lymphoblastic Leukemia: A Result of a Phase II Clinical Trial   Sasaki   Monday, Dec 7,

6:00 PM-8:00 PM

 

 

 

Hall A, Level 2

 

The following are key EVOMELATM (melphalan) for Injection -related abstracts being presented at the ASH conference:

                 
Abstract #   Type   Title   First Author   Location
3196   Poster   Phase II Study of Propylene Glycol-Free Melphalan (Evomela) Combined with Carmustine, Etoposide, and Cytarabine (BEAM) for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation   Cashen   Sunday, Dec 6,

6:00 PM-8:00 PM

 

 

Hall A, Level 2

 

The following are key ZEVALIN® (ibritumomab tiuxetan)-related abstracts being presented at the ASH conference:

                 
Abstract #   Type   Title   First Author   Location
3179 Poster Radioimmunotherapy-Based Conditioning with Yttrium-90 Ibritumomab Tiuxetan Plus High Dose BEAM for Non-Hodgkin Lymphoma: Does the Regimen Matter? Krishnan Sunday, Dec 6,

6:00 PM-8:00 PM

 

Hall A, Level 2

2707 Poster Rituximab-Pecc Induction Followed By 90y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or Have Failed ASCT: Results from a Phase II HOVON Study Lugtenburg Sunday, Dec 6,

6:00 PM-8:00 PM

 

Hall A, Level 2

3192 Poster In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials Khouri Sunday, Dec 6,

6:00 PM-8:00 PM

 

Hall A, Level 2

815   Oral   Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four Cycles of R-CHOP-14: A Multicenter Phase II Study of the Australasian Leukaemia Lymphoma Study Group (ALLG)   Hertzberg   Monday, Dec 7,

6:00PM

Tangerine 3 (WF3-4), Level 2

 

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in Oncology and Hematology. Spectrum and its affiliates market five oncology drugs─ FUSILEV® (levoleucovorin) for Injection in the U.S.; FOLOTYN® (pralatrexate injection), also marketed in the U.S.; ZEVALIN® (ibritumomab tiuxetan) Injection for intravenous use, for which the Company has worldwide marketing rights; MARQIBO® (vinCRIStine sulfate LIPOSOME injection) for intravenous infusion, for which the Company has worldwide marketing rights, and BELEODAQ® (belinostat) for Injection in the U.S. Additionally, Spectrum's pipeline includes three drugs targeting blockbuster markets in advanced stages of clinical development. Spectrum's strong track record in-licensing and acquiring differentiated drugs, expertise and proven track record in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at www.sppirx.com.

Forward-looking statement - This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to our business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, leveraging the expertise of partners and employees around the world to assist us in the execution of our strategy, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of sustained revenue history, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.

SPECTRUM PHARMACEUTICALS, INC. ®, FUSILEV®, FOLOTYN®, ZEVALIN®, MARQIBO®, and BELEODAQ® are registered trademarks of Spectrum Pharmaceuticals, Inc. and its affiliates. REDEFINING CANCER CARE™, EVOMELA™ and the Spectrum Pharmaceuticals' logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

© 2015 Spectrum Pharmaceuticals, Inc. All Rights Reserved

Spectrum Pharmaceuticals
Shiv Kapoor, 702-835-6300
Vice President, Strategic Planning & Investor Relations
InvestorRelations@sppirx.com

Source: Spectrum Pharmaceuticals

News Provided by Acquire Media